The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

被引：0
|
作者：
Ashok Jha
Alex Upton
William C. N. Dunlop
Ron Akehurst
机构：
[1] Mundipharma International Ltd.,School of Health and Related Research (ScHARR)
[2] Abacus International,undefined
[3] University of Sheffield,undefined
[4] BresMed Health Solutions Limited,undefined
[5] Northchurch Business Centre,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
Ankylosing spondylitis; Biosimilar; Crohn’s disease; Infliximab; Psoriasis; Psoriatic arthritis; Remicade; Remsima; Rheumatoid arthritis; Ulcerative colitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：742 / 756
页数：14
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS TO ASSESS THE IMPACT OF ADALIMUMAB-ATTO (BIOSIMILAR) COMPARED TO ADALIMUMAB IN AUTOIMMUNE DISEASES IN UNITED ARAB EMIRATES
    Farghally, M.
    Ahmad, Sara M. A.
    Sharma, Y.
    Shamekh, M.
    Mohamed, O.
    VALUE IN HEALTH, 2020, 23 : S412 - S412
  • [22] The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
    László Gulácsi
    Valentin Brodszky
    Petra Baji
    Fanni Rencz
    Márta Péntek
    Advances in Therapy, 2017, 34 : 1128 - 1144
  • [23] The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
    Gulacsi, Laszlo
    Brodszky, Valentin
    Baji, Petra
    Rencz, Fanni
    Pentek, Marta
    ADVANCES IN THERAPY, 2017, 34 (05) : 1128 - 1144
  • [24] REGIONAL POLICIES IMPACT ON BIOSIMILAR ADOPTION FOR AUTOIMMUNE DISEASES IN ITALY
    Tettamanti, A.
    Rova, A.
    Tucci, C.
    VALUE IN HEALTH, 2017, 20 (09) : A572 - A572
  • [25] GGDM 2016 Current "Real-Life"-Studies on the first Infliximab-Biosimilar (Remsima®) give Treatment Safety for CED
    不详
    VISCERAL MEDICINE, 2016, 32 (05) : 377 - 377
  • [26] Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn's disease patients in clinical practice: results after 6 months of treatment
    Guerra Veloz, M. F.
    Arguelles Arias, F.
    Perea Amarillo, R.
    Castro Laria, L.
    Maldonado Perez, M. B.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Vilches Arenas, A.
    Caunedo Alvarez, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S328 - S329
  • [27] 5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany.
    Kim, JiSeon
    Hong, JungAn
    Kudrin, Alex
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S512 - S512
  • [28] Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim, Yujeong
    Kwon, Hye-Young
    Godman, Brian
    Moorkens, Evelien
    Simoens, Steven
    Bae, SeungJin
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [29] Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
    László Gulácsi
    Valentin Brodszky
    Petra Baji
    Fanni Rencz
    Márta Péntek
    Advances in Therapy, 2017, 34 : 1234 - 1234
  • [30] Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment
    Guerra Veloz, M. F.
    Arguelles Arias, F.
    Perea Amarillo, R.
    Castro Laria, L.
    Maldonado Perez, M. B.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Vilches Arenas, A.
    Caunedo Alvarez, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S405 - S405
12345